Adrián Alonso-Núñez

Mr. Adrián Alonso-Núñez

Rare Diseases, Instituto de investigación Biomédica Galicia Sur (IISGS), Vigo, Galicia, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Frontiers in Marine Science
Verified
Journal Article
Open access
MCMarco J. Cabrerizo
Marco J. Cabrerizo
EMEmilio Marañón
Emilio Marañón
CFCristina Fernández-González
Cristina Fernández-González
AAAdrián Alonso-Núñez
Adrián Alonso-Núñez
HLHenrik Larsson
Henrik Larsson
MAMaría Aranguren-Gassis
María Aranguren-Gassis
Sea surface warming has the potential to alter the diversity, trophic organization and productivity of marine communities. However, it is unknown if temperature fluctuations that ecosystems naturally experience can alter the predicted impacts of warming. We address this uncertainty by exposing a natural marine plankton community to warming conditions (+3°C) under a constant vs. fluctuating (±3°C) temperature regime using an experimental mesocosm approach. We evaluated changes in stoichiometry, biomass, nutrient uptake, taxonomic composition, species richness and diversity, photosynthetic performance, and community metabolic balance. Overall, warming had a stronger impact than fluctuating temperature on all biological organization levels considered. As the ecological succession progressed toward post-bloom, the effects of warming on phytoplankton biomass, species richness, and net community productivity intensified, likely due to a stimulated microzooplankton grazing, and the community metabolic balance shifted toward a CO2 source. However, fluctuating temperatures reduced the negative effects of warming on photosynthetic performance and net community productivity by 40%. Our results demonstrate that temperature fluctuations may temper the negative effect of warming on marine net productivity. These findings highlight the need to consider short-term thermal fluctuations in experimental and modeling approaches because the use of constant warming conditions could lead to an overestimation of the real magnitude of climate change impacts on marine ecosystems.

Verified
Journal Article
Open access
PDF file
AAAdrián Alonso-Núñez
Adrián Alonso-Núñez
TPTania Pérez-Márquez
Tania Pérez-Márquez
MAMarta Alves-Villar
Marta Alves-Villar
CFCarlos Fernández-Pereira
Carlos Fernández-Pereira
JMJorge Julian Fernández Martín
Jorge Julian Fernández Martín
Saida OrtolanoSaida Ortolano
Saida Ortolano
Fabry disease is an invalidating multisystemic disorder affecting α-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect activation of inflammatory events and endothelial dysfunction. In spite of the efficacy demonstrated by enzyme replacement therapy or pharmacological chaperones in delaying disease progression, few studies have analyzed whether these treatments can improve the pro-inflammatory state of FD patients. Therefore, the aim of this work was to assess cytokines and cardiovascular risk-related proteins detectable in plasma from FD patients, whether treated or not with ERT, to evaluate the reliability of these markers in monitoring disease stage and treatment effects. We identified inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-α, GDF-15, MIP-1β, VEGFA, MPO, and MIC-1) that cooperate in a common pathway and are increased in FD patients’ plasma samples. As shown by the assessment of these proteins over time, they can help to evaluate the risk of higher severity in FD, as well as ERT effects. Even though the analyzed proteins cannot be considered as proper biomarkers due to their non-specificity to FD, taken together they can provide a signature of reference molecules with prognostic value for early diagnosis, and evaluation of disease progression and treatment efficacy, using blood samples.

24 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CFCarlos Fernández-Pereira
Carlos Fernández-Pereira
MPMaria Aránzazu Penedo
Maria Aránzazu Penedo
AAAdrián Alonso-Núñez
Adrián Alonso-Núñez
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
IVIrene Viéitez
Irene Viéitez
RARoberto Carlos Agís-Balboa
Roberto Carlos Agís-Balboa
Introduction: Bipolar disorder (BD) is a recurrent and disabling psychiatric disorder related to low-grade peripheral inflammation and altered levels of the members of the insulin-like growth factor (IGF) family. The aim of this study was to evaluate the plasma levels of IGF-2, insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, IGFBP-5, IGFBP-7, and inflammatory markers such as tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β).Methods: We used the Young Mania Rating Scale (YMRS) to determine the severity of the symptomatology, while proteins were measured by enzyme-linked immunosorbent assay (ELISA). We included 20 patients with BD who suffered a manic episode and 20 controls. Some BD patients (n = 10) were evaluated after a period (17 ± 8 days) of pharmacological treatment.Results: No statistical difference was found in IGF-2, IGFBP-1, IGFBP-7, TNF-α, and MIP-1β levels. However, IGFBP-3 and IGFBP-5 levels were found to be statistically decreased in BD patients. Conversely, the MCP-1 level was significantly increased in BD patients, but their levels were normalized after treatment. Intriguingly, only IGFBP-1 levels were significantly decreased after treatment. No significant correlation was found between the YMRS and any of the proteins studied either before or after treatment or between IGF proteins and inflammatory markers.Discussion: To some extent, IGFBP-3 and IGFBP-5 might be further explored as potential indicators of treatment responsiveness or diagnosis biomarkers in BD.